Effect of Intravenous Iron Repletion on Renal Function in Patients With Iron Deficiency and Acute Kidney Injury
Key facts
- Who runs it
- Hospital Civil de Guadalajara
- Where
- Mexico2 sites in 1 countryChoose a country to see its locations
- Trial code
- Status
- Completed
- Phase
- Phase 2
- People taking part
- 120 people enrolled
- Started
- 6 Jan 2023
- Ended
- 30 Sept 2024
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Iron dextran
- Placebo
- Record updated
- 1 October 2024
Who can take part
- Age
- 18 years to 85 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (10)Hide the full registry criteria
Who can take part
- Hospitalized patients with acute kidney injury
- iron levels <13 μmol/L or a transferrin saturation <20%
Who cannot take part
- kidney transplant
- received any red blood cell transfusion before randomization
- Chronic Kidney Disease grade 5
- less than 18 years old
- AKI within the past three months
- chronic dialysis
- hospital stay less tahn 48 hours
- missing data that would render analysis incomplete
Where is this trial?
It has locations in one country. Choose a country to see its locations.
What happens in this trial
What the trial wants to find out
This clinical trial aims to carry out research on the effect on hemoglobin and renal function of intravenous administration of iron dextran as a repletion strategy in patients with iron deficiency anemia and acute kidney injury, in which the patient may benefit from this drug as it is expected to correct anemia, ferropenia and renal function parameters, when compared with a control group (placebo), the safety of the drug will also be assessed by recording adverse effects.
Read full original descriptionShow less
The investigators will point out with the patient the risks and benefits of their inclusion in this type of study and the investigators will attend to all the doubts that are generated, as well as immediately report to the research ethics committee any serious adverse effects. The results will be presented at national and international conferences and will be published in high-impact journals, and will also be the subject of a thesis to achieve the title of specialist.
The 2 groups in the trial
- Iron dextran IVTreatment being tested
In patients with acute renal damage, they will be aleatorized to receive the administration of intravenous iron dextran 1200mg in 1 single exhibition compared to placebo.
Treatment: Iron dextran
- PlaceboPlacebo, for comparison
In patients with acute renal damage, they will be aleatorized to receive the administration of placebo.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Effect of Intravenous Iron Repletion on Renal Function in Patients With Iron Deficiency and Acute Kidney Injury, Clinical Trial
- Publications
- Record updated
- 1 October 2024